Skip to main content
MedPathMedPath Home
Clinical Trials/PER-082-02
PER-082-02
Completed
未知

CLINICAL TRIAL, CROSS, RANDOMIZED, DOUBLE BLIND, CONTROLLED AGAINST PLACEBO USING VALACICLOVIR TO REMOVE THE EXCRETION OF SIMPLE HERP VIRUS (VHS) AND HUMAN IMMUNODEFICIENCY VIRUSES (HIV) IN INDIVIDUALS COINFECTED WITH HIV TYPE 1 AND VHS TYPE 2.

GLAXOSMITHKLINE RESEARCH TRIANGLE PARK,0 sites0 target enrollmentDecember 30, 2002
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
GLAXOSMITHKLINE RESEARCH TRIANGLE PARK,
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 30, 2002
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
GLAXOSMITHKLINE RESEARCH TRIANGLE PARK,

Eligibility Criteria

Inclusion Criteria

  • •Be over 18 years of age.
  • •Be documented HIV\-1 positive.
  • •Have a CD4 count greater than 200\.
  • •Not receiving antiretroviral therapy for HIV.
  • •Be positive VHS\-2 determined by the EIA test (IN\> 3\.5\).
  • •Do not intend to travel or emigrate during the time the study lasts.

Exclusion Criteria

  • •■ Known history of adverse reactions to valacyclovir, aciclovir or famciciovir.
  • •■ Plan the open use of Aciclovir, valaciclovir, or famciciovir.
  • •■ History of seizures.
  • •■ Renal insufficiency or serum creatinine\> 2\.0 mg / dl.
  • •■ Hematocrit less than 30%.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 3
CLINICAL TRIAL, DOUBLE-BLIND, RANDOMIZED, COMPARED WITH PLACEBO TO EVALUATE THE EFFICACY AND SAFETY OF HYDROXOCOBALAMIN (VITAMIN B12) 10,000 MCG + THIAMINE HYDROCHLORIDE (VITAMIN B1) 100 MG + PYRIDOXINE HYDROCHLORIDE (VITAMIN B6) 50 MG (BEDOYECTA® TRI), COMBINATED WITH STANDARD OF CARE TREATMENT IN PATIENTS WITH CHRONIC LOW BACK PAIN.M545 Low back painLow back painM545
PER-040-21aboratorios Grossman S.A.131
Completed
Not Applicable
A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes.
PER-081-02FAMILY HEALTH INTERNATIONAL, HPTN CORE,
Active, not recruiting
Phase 1
CLINICAL TRIAL RANDOMIZED, DOUBLE-BLIND CONTROLLED, PHASE III, TO EVALUATE THE USE OF PLATELET RICH PLASMA IN FRONT HYALURONIC ACID IN COXARTHROSIS.coxarthrosisMedDRA version: 18.0Level: PTClassification code 10058417Term: Hyaluronic acidSystem Organ Class: 10022891 - InvestigationsTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
EUCTR2014-004120-21-ESFUNDACIÓN PÚBLICA ANDALUZA PROGRESO Y SALUD70
Active, not recruiting
Phase 1
SEARCH THE optimal time interval between ethyl Triptorelin and follicular puncture IN THE TREATMENT OF IN VITRO FERTILIZATIOINFERTILITYTherapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]
EUCTR2012-005571-14-ESINSTITUTO DE INVESTIGACION SANITARIA LA FE176
Active, not recruiting
Not Applicable
Crossover clinical trial, randomized, double blind, placebo controlled trial. Modulation of cellular mediators and repair endothelial damage in patients with chronic renal disease through inhibition of xanthine oxidase.Patients with chronic kidney disease and asymptomatic hyperuricemia on the balance of mechanisms of vascular injury and repair.MedDRA version: 16.1Level: LLTClassification code 10007648Term: Cardiovascular disease, unspecifiedSystem Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2013-001640-56-ESFundación Para la Investigación Biomédica de Córdoba